A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

NCT01333540 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid-induced Constipation (OIC)

Interventions

DRUG: TD-1211
DRUG: Placebo

Sponsor

Theravance Biopharma